Richard G. Gorlick

Pediatric Hematology Oncology

1515 Holcombe Blvd
Unit 0087
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 190 publications

Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma.

Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma.

Journal: Cell reports

Published: April 10, 2026

Paediatric therapeutic development workshop on osteosarcoma.

Paediatric therapeutic development workshop on osteosarcoma.

Journal: British journal of cancer

Published: April 07, 2026

Sociodemographics and Attrition in Children With Osteosarcoma Enrolled in the AOST0331 Clinical Trial.

Sociodemographics and Attrition in Children With Osteosarcoma Enrolled in the AOST0331 Clinical Trial.

Journal: JAMA network open

Published: March 27, 2026

An international framework for clinical translation of molecular classifiers in osteosarcoma.

An international framework for clinical translation of molecular classifiers in osteosarcoma.

Journal: NPJ precision oncology

Published: January 06, 2026

Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 12, 2025

Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas.

Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: October 06, 2025

Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.

Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.

Journal: International journal of radiation oncology, biology, physics

Published: August 18, 2025

Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models.

Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models.

Journal: Molecular cancer therapeutics

Published: April 22, 2025

Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group.

Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group.

Journal: Pediatric blood & cancer

Published: April 02, 2025

Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma.

Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma.

Journal: Cancer research communications

Published: April 02, 2025

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

Journal: JCO oncology advances

Published: January 01, 2025

Retraction: Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Retraction: Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Journal: Oncotarget

Published: October 11, 2024

Showing 1-12 of 190

Last Updated: 09/26/2026